Future Lipidology

Myriocin as an atherosclerosis inhibitor
pp. 221-224(4)
Author: Garner, Brett

Fatty liver and HDL-cholesterol: just a matter of quantity?
pp. 225-227(3)
Authors: Kantartzis, Konstantinos; Hääring, Hans-Ulrich; Stefan, Norbert

Compartmentalizing oxidative stress
pp. 229-231(3)
Authors: Newman, George C; Dissin, Jonathan

Results of the ENHANCE study presented
pp. 233-235(3)

Colesevelam hydrochloride: a specifically engineered bile acid sequestrant
pp. 237-255(19)
Authors: Manghat, Padmini; Wierzbicki, Anthony S

The case against ApoB and the ApoB:ApoA-I ratio: are they right?
pp. 257-264(8)
Author: Sniderman, Allan D

Potential roles for inhibitors of arachidonic acid metabolism in prevention and treatment of breast cancer
pp. 265-271(7)
Authors: Hammamieh, Rasha; Jett, Marti

Ceramide signaling in cancer and stem cells
pp. 273-300(28)
Author: Bieberich, Erhard

Phytosterols in cardiovascular disease: innocuous dietary components, or accelerators of atherosclerosis?
pp. 301-310(10)
Authors: Jessup, Wendy; Herman, Arnold; Chapman, M John

Status of cardiolipin synthesis in heart failure
pp. 311-317(7)
Author: Hatch, Grant M

Statins in stroke prevention
pp. 319-325(7)
Authors: Amarenco, Pierre; Lavalléée, Philippa C; Mazighi, Mikael; Labreuche, Julien

Evaluation of phospholipid transfer protein as a therapeutic target
pp. 327-335(9)
Authors: Vergeer, Menno; Dallinga-Thie, Geesje M; Dullaart, Robin PF; van Tol, Arie

Regulation of cellular steroid levels with special focus on oxysterol and estrogen metabolism
pp. 337-346(10)
Author: Norlin, Maria

Acknowledgements
pp. 351-351(1)